الفهرس 
CHAPTER IOnly 14 pages are availabe for public view
 |  | from | 154 |  |  |
| | | from | 154 | | |
Abstract
Key words: (mTOR – sirolimus – everolimus – kidney transplantation)
Kidney transplantation is the treatment of choice for most patients with
end-stage renal disease (ESRD). Strategies to increase donor organ
availability and to prolong the transplanted kidney’s survival have
become priorities in kidney transplantation. Current success in pediatric
renal transplantation is mostly attributed to improvement in
immunosuppressive therapy, and the provision of age – appropriate
clinical care. This review aimed to evaluate the short and long-term
benefits and harms of mammalian target of Rapamycin (mTOR)
inhibitors; Sirolimus and Everolimus when used in primary
immunosuppressive regimens for kidney transplant recipients.